Transaction DateRecipientSharesTypePriceValue
15th September 2020Advisors Llc Orbimed4,822,960Grant/award etc.$0.00
15th September 2020Advisors Llc Orbimed292,607Grant/award etc.$0.00
15th September 2020Advisors Llc Orbimed902,885Grant/award etc.$0.00
21st August 2020Holdings A/S Novo132,503Open or private purchase$24.00$3,180,072.00
21st August 2020Holdings A/S Novo4,277,300Conversion of derivative$0.00
18th August 2020Advisors Llc Orbimed43,543Open or private sale$108.54$4,726,157.22
17th August 2020Advisors Llc Orbimed94,900Open or private sale$107.49$10,200,801.00
14th August 2020Advisors Llc Orbimed20,257Open or private sale$109.03$2,208,620.71
13th August 2020Advisors Llc Orbimed29,251Open or private sale$109.93$3,215,562.43
12th August 2020Advisors Llc Orbimed42,679Open or private sale$107.45$4,585,858.55
Corvus Pharmaceuticals
Corvus Pharmaceuticals logo

Corvus Pharmaceuticals, Inc. engages in the development and commercialization of oncology therapies. The company focuses on disabling cancer's ability to subvert immune attack by inhibiting adenosine in the tumor microenvironment and by blocking its production by tumors. Its product pipeline includes Adenosine A2A Receptor Antagonist CPI-444.

Ticker: CRVS
Sector: Health Technology
Industry: Pharmaceuticals: Major
SEC Central Index Key (CIK): 1626971
Employees: 53
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Fundamentals
Cash at Carrying Value: $21 M (301%)
Other Assets, Current: $413 Th (-15%)
Assets, Current: $61 M (-23%)
Property, Plant and Equipment, Net: $1 M (0%)
Other Assets, Noncurrent: $501 Th (-2%)
Assets: $64 M (-23%)
Accounts Payable, Current: $3 M (13%)
Liabilities, Current: $12 M (12%)
Liabilities: $13 M (6%)
Common Stock, Value, Issued: $3 Th (0%)
Common Stock, Shares, Issued: $28 M (0%)
Additional Paid in Capital, Common Stock: $291 M (1%)
Retained Earnings (Accumulated Deficit): $241 M (0%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $53 Th (82%)
Stockholders' Equity (Parent): $51 M (0%)
Liabilities and Equity: $64 M (-23%)
Research and Development: $8 M (-56%)
General and Administrative Expenses: $3 M (-51%)
Operating Income/Loss: $11 M (-55%)